However, targeting a single KRAS effector or a combination of multiple downstream effectors showed modest or no clinical responses against mutant KRAS cancers in early-phase clinical trials8, 11, 12, 13; this is probably because KRAS activates multiple parallel networks and is subject to uncontrolled signalling feedback. This evidence concerns the gene KRAS and cancer.